Abstract
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread stealthily and presented a tremendous threat to the public. It is important to investigate the transmission dynamic of COVID-19 to help understand the impact of the disease on public health and economy. While a number of epidemic models have been available to study infectious diseases, they are in-adequate to describe the dynamic of COVID-19. In this paper, we develop a new epidemic model which utilizes a set of ordinary differential equations with unknown parameters to delineate the transmission process of COVID-19. Different from the traditional epidemic models, this model accounts for asymptomatic infections as well the lag between symptoms onset and the confirmation date of infection. We describe an estimation procedure for the unknown parameters in the proposed model by adapting the iterated filter-ensemble adjustment Kalman filter (IF-EAKF) algorithm to the reported number of confirmed cases. To assess the performance of our proposed model, we examine COVID-19 data in Quebec for the period of April 2, 2020 to May 10, 2020 and carry out sensitivity studies under a variety of assumptions. To reflect the transmission potential of an infected case, we derive the basic reproduction number from the proposed model. The estimated basic reproduction number suggests that the pandemic situation in Quebec for the period of April 2, 2020 to May 10, 2020 is not under control.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research is partially supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) as well as the Rapid Response Program COVID-19 of the Canadian Statistical Sciences Institute (CANSSI). Yi is Canada Research Chair in Data Science (Tier 1). Her research was undertaken, in part, thanks to funding from the Canada Research Chairs Program
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data set used is available publicly.
